Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974461 | 0.93 | PDE5A (0.82) | PDE5APDE10A | |
| SCHEMBL4975462 | 0.89 | PDE5A (0.76) | PDE5APDE10A | |
| SCHEMBL4975405 | 0.88 | PDE5A (0.82) | PDE5APDE10A | |
| SCHEMBL4977739 | 0.88 | PDE5A (1.00) | PDE5APDE10A | |
| SCHEMBL8487022 | 0.87 | PDE5A (0.80) | PDE5APDE10A | |
| SCHEMBL8507627 | 0.86 | PDE5A (0.79) | PDE5APDE10A | |
| SCHEMBL8507953 | 0.86 | PDE5A (0.78) | PDE5APDE10A | |
| SCHEMBL14326928 | 0.84 | PDE5A (0.75) | PDE5APDE10A | |
| SCHEMBL4975465 | 0.84 | PDE5A (0.75) | PDE5APDE10A | |
| SCHEMBL4979022 | 0.78 | PDE5A (0.81) | PDE5APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20040142930-A1 | Cyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030229089-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229089-A1 | Cyclic compounds | PDE3B, PDE5A, PDE9A | PDE5A 2/4885PDE10A 8/4885 |
| US-20040142930-A1 | Cyclic compounds | PDE3B, PDE4A, PDE5A | PDE5A 3/4885PDE10A 10/4885 |
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | PDE5A 4/4885PDE10A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.